Annual budgeting season is a critical time for pharmaceutical, medical device, and broader life sciences organisations.
Capital expenditure (CAPEX) decisions made now will shape research capacity, manufacturing output, and long-term competitiveness.
Yet CAPEX planning in life sciences is complex. Project teams are expected to predict costs accurately, manage risk, and allocate capital efficiently, all while navigating inflation, evolving regulatory requirements, and rapid advances in technology.
To support this, Linesight has developed a global life sciences capital project benchmarking programme built on a curated project cost database. The dataset spans hundreds of projects worldwide, including laboratories, manufacturing plants, and major facility upgrades.
Drawing on over 6,000 data points from 250 projects across 25 participating companies, the programme provides robust industry benchmarks that help leaders validate budgets, mitigate risk, and deploy capital more effectively. These insights will be explored in more detail at the Life Sciences Capital Projects Benchmarking and Performance Conference in Frankfurt on 25 March 2026.
Why benchmarking matters in CAPEX planning
Budget overruns and cost uncertainty are common in life sciences capital projects. Whether it is building a new pharmaceutical manufacturing facility, expanding R&D laboratories, or upgrading a medical device production line, project teams often face similar challenges:
Benchmarking uses up-to-date data from comparable projects to inform cost estimates, so life sciences organisations can base their CAPEX budgets on real-world evidence rather than assumptions.
By comparing a project plan against industry benchmarks, organisations can quickly identify where costs or schedules are out of line with peers and focus on the real drivers.
When CAPEX proposals are supported by benchmark statistics and references to similar successful projects, they build confidence among executives and finance committees and strengthen the case for investment.
Core features of the programme include a comprehensive dataset, where each entry captures project type, location, size, and duration alongside detailed cost and schedule breakdowns.
This structure allows teams to compare like with like and understand where performance aligns with, or deviates from, peer norms.
The programme is continuously updated with recent project data, that can reflect technology shifts, changing requirements, and inflationary pressures.
Participants access the platform through a secure Power BI dashboard, enabling visual comparisons of proposed project metrics against relevant benchmarks, including cost per square metre versus median peer data.
The platform supports benchmarking at facility, functional, and elemental levels, helping teams pinpoint where variance is occurring and why.
Contextual insights are provided with support from Linesight experts to clarify whether differences reflect scope, location, or execution strategy, enabling more informed decisions during CAPEX planning.
- Sharper CAPEX accuracy: Build robust, validated estimates grounded in real-world data.
- Data-driven decision-making: Base forecasts on 6,000+ cost and schedule benchmarks that reflect current industry norms.
- Executive confidence: Arm senior stakeholders with transparent, defensible evidence to support CAPEX allocations.
- Comparability and transparency: Understand how projects align with peers and industry norms.
- Risk mitigation: Identify outliers and cost/schedule drivers early to prevent overruns.
- Credibility: Build internal and external trust in budgets and schedules.
How to get involved
Registrations are now being reviewed for the Life Sciences Capital Projects Benchmarking and Performance Conference in Frankfurt on 25 March 2026. This is an ideal opportunity to learn more about the programme and explore how your organisation can participate.
If you cannot make the event but are interested in joining the benchmarking initiative, contact Jonathan Phillips using the form at the top of this page to learn more about the programme and how your organisation can get involved.
In an industry as dynamic and high stakes as life sciences, data-driven CAPEX planning is not just a finance exercise but a strategic advantage.
By leveraging Linesight’s Life Sciences Benchmarking Programme, organisations can ground their budgets in reality, defend them with confidence, and uncover cost efficiencies that might otherwise be overlooked. The programme’s rich data and insights help turn the daunting task of annual budgeting into a more streamlined, transparent, and strategic process.
